Syngene to Launch GMP Bioconjugation Suite in Bengaluru

Syngene International Ltd., a global leader in contract research, development, and manufacturing (CRDMO) services, has unveiled plans to set up a cutting-edge GMP bioconjugation suite at its commercial biologics facility (Unit 3) in Bengaluru.

This new addition will empower Syngene to deliver fully integrated, end-to-end solutions for antibody-drug conjugates (ADCs), spanning early-stage discovery to GMP-compliant manufacturing, placing the company among a select group of CDMOs offering comprehensive ADC development capabilities.

Designed to meet OEB-5 standards, the suite will streamline ADC development by enabling both monoclonal antibody (mAb) production and GMP bioconjugation within the same location. The initiative builds on Syngene’s established expertise in payload and linker manufacturing at the commercial scale.

Also Read: Ipsen to Acquire ImCheck Therapeutics to Boost Cancer Pipeline

Scheduled to become operational within the current financial year, the facility will also accommodate the production of a variety of advanced conjugates and related therapeutic modalities.

By integrating analytical and bioanalytical functions on-site, Syngene aims to enhance workflow efficiency, ensure seamless data integration, and maintain stringent quality control across every stage of the development and manufacturing process.

“The discovery and development of ADCs is inherently complex, often involving multiple vendors and geographically dispersed sites, which introduces supply chain  challenges and delays,” said Alex Del Priore, Head – LM CDMO, Syngene International.